Literature DB >> 2457199

Primary carcinoid tumour of the larynx.

A Ferlito1, I Friedmann, N C Goldman.   

Abstract

Carcinoid neoplasms, although rare, have to be considered in the differential diagnosis of neoplasms of the larynx. The total number of cases reviewed and listed in the present article is 47. The gross appearance of carcinoid tumours is not characteristic and does not differ from that of other malignant neoplasms of the larynx. Under the light microscope various types can be distinguished, which are described and illustrated in this review article. Available material of five previously published cases and of one new case have been re-examined under the electron microscope and by modern histochemical and immunohistochemical methods. The ultrastructural presence of neurosecretory granules and of argyrophilia by the Grimelius technique were uniformly positive, together with monoclonal antibodies for somatostatin and keratin. These special methods offer a reliable basis for the diagnosis of neuroendocrine neoplasms to which carcinoid tumours belong. The treatment of carcinoid neoplasms of the larynx is surgical.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457199     DOI: 10.1159/000275982

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  3 in total

1.  Carcinoid tumour of the larynx: a case report and clinico-pathological review.

Authors:  T G O'Leary; B Kotecha; D Butterworth
Journal:  Ir J Med Sci       Date:  1991-04       Impact factor: 1.568

2.  Immunohistochemical and fine structural characterization of primary carcinoid tumors of the larynx.

Authors:  R Dieler; J Dämmrich
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

3.  Neuroendocrine neoplasms of the larynx. Importance of the correct diagnosis and differences between atypical carcinoid tumors and small-cell neuroendocrine carcinoma.

Authors:  F M Gripp; E K Risse; H Leverstein; G B Snow; C J Meijer
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.